Aubagio® is the commercial brand name of Teriflunomide Tablets, an orally active immunomodulatory agent developed by Sanofi. It inhibits dihydroorotate dehydrogenase to suppress the proliferation of activated T and B lymphocytes, reducing autoimmune inflammatory damage in the central nervous system.
Main Indications
Treatment of adult patients with relapsing multiple sclerosis (RMS) to reduce the frequency of clinical relapses and slow the progression of neurological disability.
Clinical Research
Global phase III pivotal trials confirmed that oral teriflunomide effectively lowers annualized relapse rates and reduces active lesions on brain MRI in patients with relapsing multiple sclerosis;
Long-term extension studies validated sustained clinical benefits and a stable safety profile during long-term administration;
Clinical trials enrolling Asian subjects demonstrated consistent efficacy and tolerability consistent with global research outcomes.
Common Side Effects
Severe but important risks: Hepatic injury, peripheral neuropathy, teratogenic risk, severe skin adverse reactions;
Common mild adverse reactions: Headache, diarrhea, nausea, alopecia, elevated liver enzymes, fatigue and arthralgia.
Approval Status in China
Original drug Aubagio® (Teriflunomide Tablets) was officially approved for marketing in China in 2018, with the specification of 14 mg per tablet, 28 tablets per box. It is currently a prescription drug included in China’s Category B medical insurance catalogue.
Buy Aubagio (Teriflunomide Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
